Core Insights - The research team from the Chinese Academy of Sciences has successfully completed the second clinical trial of an invasive brain-machine interface (BMI) that allows a high-level paraplegic patient to control a smart wheelchair and robotic dog using brain signals [1][2] - The technology aims to establish a direct communication channel between the brain and external devices, overcoming challenges in integrating this technology into patients' daily lives [1] Group 1: Technological Breakthroughs - The research team developed a high-compression, high-fidelity neural data compression technology, enhancing brain control performance by 15% to 20% even in noisy environments [2] - The introduction of "neural manifold alignment technology" allows for the extraction of stable low-dimensional features from high-dimensional dynamic neural signals, improving the decoder's adaptability to environmental changes [2] Group 2: Performance Enhancements - The end-to-end delay from signal acquisition to command execution has been reduced to under 100 milliseconds, providing a smoother and more natural control experience for patients [2] - The team has innovated an "online recalibration technology" that allows real-time adjustments to decoding parameters during daily use, ensuring sustained high performance without interrupting the patient's operation [2] Group 3: Future Developments - A new upgraded version of the system (WRS02) has been launched, with further performance improvements, and the team plans to conduct the first clinical trial of this version soon [2]

证券日报网讯12月19日，美好医疗（301363）在互动平台回答投资者提问时表示，脑机接口产品的成熟 度和应用场景随着下游客户产品的成熟和完善性能不断提高。公司正与下游脑机接口客户深入开展产品 合作，协助客户实现从实验室研发到批量出货的高效商业化转化，目前相关业务产生的收入规模较小， 具体客户及合作细节涉及商业机密不便回复。 ...

据智通财经12月19日讯，据国家药监局消息，12月18日，国家药监局在北京召开脑机接口医疗器械工作 推进会。会议听取高等院校、科研院所、医疗机构相关专家学者和研发企业代表意见建议。国家药监局 党组成员、副局长雷平出席会议并讲话。 会议要求，要深入贯彻落实党的二十届四中全会精神，深刻领会脑机接口作为前瞻布局未来产业的重要 战略意义；要坚持安全有效为首要前提，创新审评监管方法，构建标准体系，加强技术指导服务；要加 强跨部门合作，联手产学研医各方，合力解决关键技术问题，完善产业链供应链；要落实企业主体责 任，以问题为导向，提升产品可靠性和整体竞争力，积极推动脑机接口器械更快更好服务临床、惠及患 者。 国家药监局器械注册司、标管中心、器审中心负责同志及有关人员参加会议。 相关市场板块分析 医疗器械与康复设备：脑机接口技术率先在医疗康复领域落地，多家公司产品进入临床试验阶段，相关 医疗器械企业迎来技术升级与需求扩张，市场潜力巨大。 人工智能与大数据：脑机接口依赖高精度算法与海量数据处理，AI企业在脑电信号解码、情绪识别、 脑电大模型等领域深度布局，推动技术迭代。 消费电子与智能穿戴：非侵入式脑机接口在游戏、教育、疲劳监 ...

Group 1: Event Overview - The first Hong Kong International AI Art Festival opened with a speech by the CEO of Qiangnao Technology, highlighting the acceleration of innovation in Hong Kong [1] - The festival's theme is "Envisioning the Future: Reality and Boundlessness," and the CEO delivered a talk titled "Brain-Computer Interface: A Century-Long Project of Humanity" [1] Group 2: Company Developments - Qiangnao Technology has officially settled in Hong Kong Cyberport, emphasizing Hong Kong's vibrant and culturally diverse environment [2] - The company aims to bring its leading non-invasive brain-computer interface technology to Hong Kong and establish a robust industrial ecosystem [2] Group 3: Technology and Applications - Qiangnao Technology focuses on becoming a global leader in non-invasive brain-computer interface solutions, with advantages in rehabilitation, health, human-computer interaction, and more [4] - The brain-computer interface technology is recognized as a platform technology applicable in various fields, including medical, educational, and entertainment sectors [4] - The company plans to assist 1 million individuals with physical disabilities, 10 million patients with brain diseases, and 100 million people to experience the convenience of brain-computer interface products over the next 5 to 10 years [4] Group 4: Product Recognition - The company's smart bionic hand has received multiple accolades, including being the first brain-computer interface prosthetic approved by the FDA and being recognized as one of TIME magazine's best inventions of the year [6] - These recognitions signify the transition of brain-computer interfaces from laboratory settings to real-world applications [6] Group 5: Cultural and Artistic Integration - The successful hosting of the Hong Kong International AI Art Festival marks a new exploration in the integration of cultural innovation and technology [7] - The CEO emphasized the convergence of art and science, quoting Gustave Flaubert to illustrate that both fields are increasingly interlinked [7] - A notable demonstration included a young user with a disability who was able to paint again using Qiangnao Technology's smart bionic hand, showcasing the potential of technology to restore creativity [8]

强脑科技正式入驻香港数码港 " 我们已经正式入驻香港数码港。 " 韩璧丞表示，香港是一个非常有活力、融合了东西方智慧的地方。 韩璧丞表示，强脑科技从波士顿的哈佛实验室起步，逐步走向奥斯汀、深圳、杭州，现在来到香港。强脑科技希望能把全球领先的脑机接 口技术带到香港，并在香港建立一个很好的产业生态。 【导读】首届香港国际 AI 艺术节开幕，强脑科技 CEO ：在香港，创新正加速涌动 中国基金报记者 邱德坤 " 在香港，我们看到的，不只是金融的流动，还有创新正加速涌动。 " 在 12 月 19 日举行的首届香港国际 AI 艺术节开幕式上，强脑科技 创始人兼 CEO 韩璧丞发表演讲称。 首届香港国际 AI 艺术节由紫荆文化集团主办，主题为 " 预见未来：现实与无界 " 。在开幕式上，韩璧丞发表题为《脑机接口 —— 人类的 百年工程》的演讲。 来源：强脑科技 公司官网显示，强脑科技致力于成为全球领先的非侵入式脑机接口技术解决方案供应商，在康复、大健康、人机交互等领域具有优势。 脑机接口技术作为平台性技术，可以应用在人机交互及工业应用、医疗、教育、健康、娱乐等领域。在 " 十五五 " 规划建议中，脑机接口 技术被列为六大 ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing a significant surge in stock prices, driven by recent developments in regulatory support and technological advancements [1]. Group 1: Stock Performance - Nanjing Panda (00553) increased by 4.16%, reaching HKD 4.51 [1] - MicroPort NeuroTech (02172) rose by 4.24%, trading at HKD 10.83 [1] - BrainCo (06681) saw a 2.58% increase, priced at HKD 5.96 [1] Group 2: Regulatory Developments - The National Medical Products Administration held a meeting on December 18 to advance BCI medical device initiatives [1] - The meeting emphasized the strategic importance of BCI in future industry development and the need for safety and effectiveness as primary considerations [1] - It called for innovative regulatory methods, the establishment of standard systems, and enhanced technical guidance [1] Group 3: Industry Outlook - According to Guotai Junan, the BCI industry is poised for significant growth due to technological breakthroughs, policy support, and capital investment [1] - There is an anticipated release of demand in downstream markets such as healthcare and consumer goods, indicating a promising market outlook [1]

Core Viewpoint - The Hong Kong stock market is experiencing a surge in brain-computer interface concept stocks, indicating growing investor interest in this sector [1] Group 1: Stock Performance - Nanjing Panda (00553.HK) increased by 4.16%, reaching HKD 4.51 [1] - Weikang Brain Science (02172.HK) rose by 4.24%, trading at HKD 10.83 [1] - Brain Motion Aurora-B (06681.HK) saw a gain of 2.58%, priced at HKD 5.96 [1]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing a significant surge in stock prices, driven by government support and technological advancements, indicating a promising market outlook for the industry [1] Group 1: Stock Performance - Nanjing Panda (600775) shares increased by 4.16%, reaching HKD 4.51 [1] - Microwin Brain Science (02172) shares rose by 4.24%, reaching HKD 10.83 [1] - Brain Motion Aurora-B (06681) shares grew by 2.58%, reaching HKD 5.96 [1] Group 2: Regulatory Developments - The National Medical Products Administration held a meeting on December 18 to advance BCI medical device initiatives [1] - The meeting emphasized the strategic importance of BCI in future industry development and the need for safety and effectiveness as primary considerations [1] - It called for enhanced cross-departmental collaboration to address key technical challenges and improve the industry supply chain [1] Group 3: Market Outlook - According to Guotai Junan, the BCI industry is expected to benefit from technological breakthroughs, policy support, and capital investment [1] - There is an anticipated release of demand in downstream markets such as healthcare and consumer goods, indicating a positive market outlook [1]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing a surge in stock prices, driven by recent government initiatives and the potential for significant market opportunities in healthcare and consumer sectors [1] Industry Summary - The National Medical Products Administration held a meeting on December 18 to promote the development of medical devices related to brain-computer interfaces, emphasizing the strategic importance of BCIs for future industries [1] - The meeting highlighted the need for safety and effectiveness as primary considerations, along with innovative regulatory methods and the establishment of a standard system [1] - There is a call for enhanced collaboration across various sectors, including industry, academia, and healthcare, to address key technological challenges and improve the supply chain [1] - Companies are urged to take responsibility for product reliability and competitiveness, aiming to expedite the clinical application of BCI devices for patient benefit [1] Company Summary - Stocks of companies involved in the BCI sector, such as Nanjing Panda (up 4.16% to HKD 4.51), MicroPort NeuroTech (up 4.24% to HKD 10.83), and BrainCo (up 2.58% to HKD 5.96), have seen significant increases [1] - Analysts from Guotai Junan point out that the BCI industry is poised for substantial growth due to technological breakthroughs, policy support, and capital investment, indicating a promising market outlook [1]

Group 1 - The core viewpoint of the articles highlights the significant advancements in brain-computer interface (BCI) technology in China, particularly its application in enhancing the quality of life for patients with severe disabilities [1][2] - A recent experiment demonstrated a paralyzed patient controlling an electric wheelchair and a robotic dog using an invasive brain-computer interface, marking a shift from basic interaction capabilities to real-world applications [1] - The research emphasizes the importance of addressing patients' multidimensional life needs, moving beyond mere functional restoration to enabling autonomy and social participation [1] Group 2 - China's development path in BCI technology is becoming clearer, with national guidelines and multi-departmental initiatives promoting ethical research and clinical application [2] - The collaborative model of "research-clinical-industry" is accelerating the translation of scientific discoveries into real-world benefits for patients [2] - Challenges remain in ensuring the long-term safety, system stability, and affordability of invasive BCIs, as well as improving the interpretation of neural signals and human-computer interaction [2]